FDA Approved: DEFEROXAMINE MESYLATE — Supplemental Application (Hospira, Inc.)

View source ↗

Summary

FDA approved Hospira's supplemental application for Deferoxamine Mesylate, enabling its continued marketing as an iron chelation therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia with Transfusional Iron Overload
• Iron Overload
• Iron Poisoning

Drugs mentioned

• Deferoxamine Mesylate (Deferoxamine)

Snippet

SUPPL AP for DEFEROXAMINE MESYLATE (DEFEROXAMINE MESYLATE)